"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
| Descriptor ID |
D007167
|
| MeSH Number(s) |
E02.095.465.425
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in this website by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 3 | 3 |
| 1999 | 0 | 3 | 3 |
| 2000 | 4 | 2 | 6 |
| 2001 | 2 | 5 | 7 |
| 2002 | 5 | 6 | 11 |
| 2003 | 4 | 5 | 9 |
| 2004 | 5 | 3 | 8 |
| 2005 | 6 | 2 | 8 |
| 2006 | 2 | 2 | 4 |
| 2007 | 4 | 3 | 7 |
| 2008 | 3 | 7 | 10 |
| 2009 | 12 | 7 | 19 |
| 2010 | 8 | 7 | 15 |
| 2011 | 9 | 7 | 16 |
| 2012 | 3 | 10 | 13 |
| 2013 | 10 | 7 | 17 |
| 2014 | 17 | 11 | 28 |
| 2015 | 7 | 7 | 14 |
| 2016 | 13 | 6 | 19 |
| 2017 | 19 | 13 | 32 |
| 2018 | 18 | 13 | 31 |
| 2019 | 14 | 16 | 30 |
| 2020 | 25 | 15 | 40 |
| 2021 | 14 | 24 | 38 |
| 2022 | 2 | 31 | 33 |
| 2023 | 3 | 21 | 24 |
| 2024 | 13 | 17 | 30 |
| 2025 | 19 | 7 | 26 |
| 2026 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
Safety and effectiveness of immune checkpoint inhibitors in older adults with metastatic non-small cell lung cancer and pre-existing autoimmune disease - A SEER-Medicare study. J Geriatr Oncol. 2026 May; 17(4):102971.
-
Established and Emerging Therapies for High-Risk Neuroblastoma. Paediatr Drugs. 2026 Mar; 28(2):159-175.
-
Immunotherapy of TSA-1.C4 or in combination with BNZ confers protection against Trypanosoma cruzi infection with a distinct cytokine response. Vaccine. 2026 Mar 19; 76:128296.
-
Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers. Nat Commun. 2026 Jan 03; 17(1):1193.
-
Consequences of adverse events in cancer immunotherapy combinations - a comprehensive real-world analysis. Immunotherapy. 2025 Nov; 17(16):1177-1187.
-
Serum Arginase-1 is a predictive biomarker for melanoma patients and a surrogate indicator of systemic myeloid cell fitness. Oncoimmunology. 2025 Dec 31; 14(1):2595764.
-
The challenge of deintensifying chemotherapy for children and adolescents with B-ALL in the immunotherapy era. Hematology Am Soc Hematol Educ Program. 2025 Dec 05; 2025(1):229-235.
-
Reverse Lipid Droplet Function for Hepatocellular Carcinoma Immunotherapy. Angew Chem Int Ed Engl. 2026 Jan 22; 65(4):e20609.
-
Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2025 12; 23(12).
-
Translational advancement of immunotherapeutics against pediatric central nervous system tumors. Adv Cancer Res. 2025; 167:327-358.